Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

South Africa ‘Forced To Overpay’ For COVID-19 Vaccines Under ‘One-Sided’ Contracts

Executive Summary

Companies and organizations that signed the contracts deny any heavy-handedness, with Johnson & Johnson saying it worked closely with South Africa on vaccine supply, and the vaccine alliance Gavi noting that the COVAX Facility provided the country with more than nine million doses free of charge.

You may also be interested in...



Aspen Appears Unfazed As Potential Difficulties Loom

Analysts posted wary notes about the prospects of South African pharmaceutical firm Aspen as its financial year came to an end, while management maintained confidence in the firm’s “solid results.”

South African Court Orders Release Of COVID-19 Vaccine Contracts

The High Court’s decision could have consequences for the negotiation of vaccine contracts in other countries and might also lead to a strengthening of the provisions on transparency and accountability in talks on a future pandemic treaty, says the Health Justice Initiative.

Austria & Germany Call For ‘Competitiveness Check’ On EU Pharma Revision Package

The two countries want the European Commission’s proposals to be more closely examined for their possible negative effect on pharmaceutical investment decisions. The industry federation EFPIA says it is surprised more EU member states aren’t taking the same stance.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148822

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel